Agarwal, Anubha http://orcid.org/0000-0002-7090-5601
Mehta, Priya M. http://orcid.org/0009-0000-4392-0462
Jacobson, Tyler http://orcid.org/0000-0002-9655-1186
Shah, Nilay S.
Ye, Jiancheng
Zhu, JingJing
Wafford, Q. Eileen
Bahiru, Ehete
de Cates, Angharad N.
Ebrahim, Shah
Prabhakaran, Dorairaj
Rodgers, Anthony
Huffman, Mark D. http://orcid.org/0000-0001-7412-2519
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K99HL157687)
Doris Duke Charitable Foundation (Grant 2020144)
Article History
Received: 22 September 2023
Accepted: 1 March 2024
First Online: 26 March 2024
Competing interests
: M.D.H. has received travel support from the World Heart Federation. M.D.H. and A.R. have an appointment at The George Institute for Global Health, which has a patent, license and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. George Health Enterprises Pty Ltd, the social enterprise arm of the George Institute for Global Health (TGIGH), has received investment to develop fixed-dose combination products containing aspirin, statin and BP-lowering drugs. The George Institute for Global Health holds and have filed applications for combination products for the treatment of hypertension and diabetes, and A.R. is listed as one of the inventors (granted: US 10,369,15; US 10,799,487; US 10,322,117; US 11,033,544; and US 11,478,462 and pending: US 17/932,982; US 18/446,268; US 17/598,122; and US 17/317,614). A.R. is seconded part-time to George Medicines Pty Ltd, a subsidiary of George Health Enterprises. A.R. does not have a personal financial interest in these patents or products. M.D.H. and A.A. have pending patents for heart failure polypills. The other authors declare no competing interests.